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Summary. Angiogenesis is a dynamic, hypoxia-
stimulated and growth factor-dependent process,
eventually leading to the formation of new vessels from
pre-existing blood vessels. In the last decade
experimental and clinical studies have described the
occurrence of hepatic angiogenesis in a number of
different pathophysiological conditions, including those
involving inflammatory, fibrotic and ischemic features.
In particular, the literature evidence indicates that
hepatic angiogenesis is strictly associated with, and may
even favour fibrogenic progression of chronic
inflammatory liver diseases of different aetiology. In this
review, current “in vivo” and “in vitro” evidence
supporting the potential pathogenetic role of
angiogenesis in chronic liver diseases will be reviewed
in an attempt to outline cellular and molecular
mechanisms involved, with a specific emphasis on the
crucial role of hypoxic conditions and hepatic stellate
cells (HSCs), particularly when activated to the
myofibroblast-like pro-fibrogenic phenotype. 
Key words: Liver angiogenesis, Hepatic stellate cells,
Hepatic myofibroblasts, VEGF, Pro-angiogenic
cytokines
1. Blood vessel formation and remodelling:
introductory remarks and the aim of the review
Blood vessels have a fundamental role in delivering
oxygen, nutrients and several biologically active
molecules, as well as blood and cells of the immune
system, to all tissues, and indeed constitute the first
organ during embryo development and form the largest
network in the human body (Carmeliet, 2003; Jain,
2003). Small and/or nascent blood vessels are simply
composed of endothelial cells (ECs) whereas the walls
of the largest and mature blood vessels are formed by
ECs and mural cells, which are embedded in an
extracellular matrix (ECM), with “mural cells” being a
general definition usually including pericytes (as in
medium-sized vessels) and smooth muscle cells (SMCs,
as in the largest vessels). 
Blood vessels can be formed and grow by means of
several major processes that the current literature refers
to as vasculogenesis, angiogenesis, arteriogenesis and
collateral vessel growth (Carmeliet, 2003, 2004). 
Vasculogenesis
This term has been used for a long time simply to
denote “de novo” blood vessel formation during
embryogenesis, in which angiogenic progenitor cells
(hemangioblasts present in the different tissues/organs)
are able to migrate to the sites of vascularization where
they differentiate into ECs and start to form the initial
vascular plexus (Carmeliet, 2003). In recent years
several laboratories have shown that in addition to this
“prenatal vasculogenesis”, ECs can be formed in the
adult (postnatal vasculogenesis) by endothelial
progenitor cells (EPCs), mesangioblasts, multipotent
adult progenitor cells or so-called side-population cells.
Moreover, endothelial progenitors are likely to
significantly contribute to EC formation in adult life,
particularly in the presence of ischemic, malignant or
chronic inflammatory conditions. 
Angiogenesis
This process is usually referred to as a dynamic,
hypoxia-stimulated and growth factor dependent
process, eventually leading to the formation of new
vessels from pre-existing blood vessels. Formation of
new vessels by the process of angiogenesis can occur
virtually in almost all tissues and organs and is
considered a critical step for tissue repair and growth in
Review
Angiogenesis and liver fibrogenesis
Lorenzo Valfrè di Bonzo, Erica Novo, Stefania Cannito, 
Chiara Busletta, Claudia Paternostro, Davide Povero and Maurizio Parola
Department of Experimental Medicine and Oncology and 
Interuniversitary Centre of Hepatic Pathophysiology, University of Torino, Italy
Histol Histopathol (2009) 24: 1323-1341
Offprint requests to: Maurizio Parola, Dip. Medicina e Oncologia
Sperimentale, Università degli Studi di Torino, Corsoo Raffaello 30,




Cellular and Molecular Biology
several pathophysiological conditions (Yancopoulos et
al., 2000; Carmeliet, 2003; Ferrara et al., 2003; Jain,
2003; Pugh and Ratcliffe, 2003). Although from an
historical point of view angiogenesis has been originally
implicated mainly in cancer, arthritis and psoriasis, as
well as in many other diseases, today several
laboratories suggest that pathological angiogenesis, then
the formation of new vessels occurring during clinical
conditions characterized by persisting inflammation,
chronic wound healing and fibrogenesis, may provide a
key contribution to disease progression (Carmeliet,
2003, 2004). 
Arteriogenesis
This term refers to a process consisting of the
remodelling of existing blood vessels in which ECs have
already been differentiated into arterial ECs to increase
luminal diameter in response to increased blood flow, a
process that usually requires recruitment of SMCs. 
Collateral vessel growth
This definition is employed to identify a process
characterized by the expansive growth of pre-existing
vessels that are then able to form collateral bridges
between arterial networks.
The aim of the present review is to first offer a brief
overview of the major basic mechanisms and events in
angiogenesis, followed by an analysis of those cellular
and tissue peculiarities that are likely to make hepatic
angiogenesis significantly differ from homologous
processes in other tissues or organs. The bulk of the
review will be focussed on critically analysing all most
recent results suggesting that, irrespective of aetiology,
hepatic angiogenesis is likely to favour fibrogenic
progression of chronic liver diseases (CLDs), with liver
myofibroblasts (MFs) playing a crucial role, being able
to act as pro-angiogenic cells, as well as cellular targets
of pro-angiogenic cytokines and growth factors.
Physiological angiogenesis (i.e., angiogenesis occurring
after partial hepatectomy) will be shortly analysed,
whereas the crucial relationships between angiogenesis
and hepatocellular carcinoma or metastatic liver cancers,
which for their relevance should deserve an independent
analysis, will not be mentioned here. Interested readers
may refer to recently published more comprehensive
reviews (Medina et al., 2004; Lee et al., 2007; Kerbel,
2008). 
2. Hypoxia as a major stimulus for angiogenesis
Hypoxia can be simply defined as an oxygenation
state that is below the norm for a particular tissue.
Several studies have pointed out that in the human body
the average tissue partial pressure of oxygen (pO2) is
usually higher than 20 mm of Hg and that true hypoxic
conditions may exist when pO2 is below the limit of 10
mm of Hg (Vaupel et al., 2001; Dewhirst et al., 2008).
By definition, cells react to the reduced levels of pO2 by
involving critical molecular mediators belonging to the
family of hypoxia-inducible factors (HIFs) that facilitate
oxygen delivery and adaptation to decreased oxygen
levels by up-regulating several genes carrying the so-
called hypoxia response elements (HRE) sequences in
their promoter or enhancer. Sufficient to this review (the
interested reader can refer to more detailed and
comprehensive reviews by Semenza, 2001, 2004;
Rankin and Giaccia, 2008) are the following major
concepts. 
1) At present three HIFs have been characterized (HIF-1,
-2 and -3) which are all heterodimers formed by an
oxygen sensitive and inducible HIF-α subunit and a
constitutive, oxygen-independent, HIF-ß subunit (the
latter known also as arylhydrocarbon receptor nuclear
translocator or ARNT). The best characterized member
of this family of transcription factors is HIF-1, which is
formed by HIF-1α and HIF-1ß or ARNT.
2) Under normoxic conditions, HIF-1α is continuously
modified by a number of enzymes (hydroxyl-proline
hydroxylases or HPHs; asparaginyl hydroxylase FIH1)
whose activity is dependent on oxygen levels. Two
major mechanisms are known that prevent the formation
of transcriptional complexes able to translocate into the
nuclei and bind HRE sequences: a) HIF-1α, when
hydroxylated on proline residues and/or acetylated on
lysine residue in normoxic conditions, binds to the von
Hippel-Lindau protein and other polypeptides forming a
multi-subunit complex that is ubiquitylated and
continuously degraded via proteasomes; b) alternatively,
FIH1 can hydroxylate an asparagine residue of HIF-1α.
3) Under hypoxic conditions HPHs and/or FIH1 are
progressively inhibited and HIF-1α can form the
heterodimer with ARNT; HIF1 is then phosphorylated/
stabilized by intervention of kinases and can form the
ultimate transcriptional complex able to bind HRE
sequences.
4) Sets of genes that are activated in a HIF-1-dependent
manner include those involved in: a) vasomotor control
and erithropoiesis, such as inducible NO synthase,
endothelin 1 and erythropoietin; b) energy metabolism,
such as glucose transporters (mainly GLUT-1 and -3)
and several glycolytic enzymes; c) cell survival,
including a number of ion transporters and exchangers
able to regulate intracellular pH; d) cell proliferation and
cell cycle; e) angiogenesis and ECM degradation and
remodeling, including members of the VEGF family and
related receptors, angiopoietins and related receptors,
collagen prolyl-4-hydroxylase, the receptor for
urokinase-plasminogen activator or uPA-R and the
plasminogen activator inhibitor type 1 (PAI-1), to name
just a few. 
Relevant to this review, two more concepts should
be recalled. First, it should be remembered that there are
tissues or tissue areas in which pO2 is low even in
normal conditions: this occurs in the normal liver where
the first rim of perivenular hepatocytes has been
described to be under conditions of partial hypoxia, as
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confirmed by the fact that these cells are positive to
immunohistochemistry for HIF-1 (nuclei) and VEGF
(cytoplasm), as well as for pimonidazole adducts (Arteel
et al., 1995; Rosmorduc et al., 1999; Bozova and Elpek,
2007; Dewhirst et al., 2008). Second (Dewhirst et al.,
2008), one should always remember that although under
hypoxia HIF-1α activation is mostly obtained by post-
translational mechanisms, there are conditions that are
able either to lead to increased HIF-1α mRNA
transcription (including cytokines, growth factors,
oncogenes, metabolic stress and reactive oxygen species
or ROS operating through activation of PI3K and
Ras/Erk signalling pathways) or to HIF-1α increased
stabilization (for example, following direct interaction
with ROS). This scenario, in which HIF-1α may operate
also independently on hypoxic conditions, is likely to
play a role in conditions of CLDs. 
3. Angiogenesis: basic mechanisms and events
Angiogenesis is a common event in CLDs (Medina
et al., 2004) and is likely to be mostly dependent on the
development of hypoxic conditions and of cellular
responses mediated by the hypoxia-inducible factors.
HIFs upregulate several angiogenic genes (Fig. 1) but
the induction of vascular endothelial growth factor
(VEGF) is perhaps the most remarkable one, and its
increased transcription is rapid and impressive (up to 30
fold, depending on the specific cell type). VEGF can
sustain both physiological and pathological
angiogenesis, whereas other members of the VEGF
family may have a role only in pathological
angiogenesis, like placental growth factor (PlGF).
Several other molecules are able to regulate
angiogenesis, including growth factors, cytokines,
chemokines, lipid mediators, hormones, neuropeptides
and, possibly, also reactive oxygen species (ROS). A
detailed analysis of cellular and molecular mechanisms
controlling angiogenesis is beyond the scope of the
present review and here only major general steps and
events of the process will be schematically recalled
(Carmeliet, 2003; Ferrara et al., 2003; Pugh and
Ratcliffe, 2003; Medina et al., 2004; Dewhirst et al.,
2008). 
3.1 Sprouting and budding
If one considers quiescent vessels as the starting
condition and hypoxia as the major initiating stimulus
for angiogenesis, the first events are those depending on
the action of nitric oxide (NO) and VEGF that can lead
ECs to migrate and proliferate in order to allow new
blood vessels to grow and branch. As depicted in Figure
2A, endothelial budding requires NO-dependent
vasodilation and VEGF-induced increased vascular
permeability with loosening of all those inter-endothelial
contacts that in quiescent vessels provide mechanical
strength and tightness and establish a permeability
barrier. This includes mainly vascular endothelial
cadherin in adherens junctions and claudins, occludins
and junctional adhesion molecules (JAMs) in tight
junctions, but also relevant are contacts through CD31
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Fig. 1. Target genes for HIF-1 in mediating hypoxia-induced
angiogenesis.
(PECAM1) and intercellular communications through
connexins in gap junctions. Vasodilation and loosening
of interendothelial contacts will result in leakiness of
pre-existing vessels, leading to extravasation of plasma
proteins that, together with extracellular matrix (ECM)
components, will form a provisional scaffold or path for
ECs to migrate. The main antagonist stimulus to these
starting events in angiogenesis is represented by
Angiopoietin-1 (Ang1), which tightens interendothelial
contacts (Figs. 2A, 3).
3.2 ECM degradation and EC migration
In order to allow ECs to migrate, proliferate and then
form new sprouts, the ECM network of pre-existing
vessels (including basement membrane, as well as an
interstitial matrix of elastin and collagen type I between
vascular cells) has to be submitted to a carefully
controlled and equilibrated process of proteolytic
remodelling (Fig. 2B). ECM proteolytic remodelling is
sustained by a number of proteinases and related
inhibitors that include: a) matrix metalloproteinases
(MMPs) and their tissue inhibitors (TIMPs), b)
plasminogen activators (mainly urokinase plasminogen
activator or uPA and its physiological inhibitor PAI-1),
c) other proteinases, including heparinases and
cathepsins. Proteinases can also contribute to EC
migration by either liberating ECM-bound pro-
angiogenic factors like VEGF, basic fibroblast growth
factor (bFGF) and transforming growth factor ß1
(TGFß1), or by proteolitically activating other factors.
Moreover, as a consequence of proteolytic remodelling,
migration of ECs (and possibly pericytes and smooth
muscle cells) may also be facilitated by exposure of
cryptic epitopes in ECM proteins or by disruption of
integrin-mediated contacts between ECs and ECM
(Carmeliet, 2003). However, it should be mentioned that
some integrins (αvß3 and αvß5) may also act as anti-
angiogenic factors by inhibiting VEGF and VEGF
receptor Type 2 (VEGFR-2 or Flk-1) mediated survival
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Fig. 2. Different stages of angiogenesis. A. Sprouting and budding due to endothelial cells (EC) proliferation and migration, mainly stimulated by
hypoxia. B. Extracellular matrix (ECM) remodeling and EC migration and proliferation. C. Lumen formation and 3D organization. D. Stabilization of
nascent vessels.
of ECs. The relevance of proteolytic remodelling for
angiogenesis is confirmed by two opposite findings, both
resulting in inhibition of angiogenesis (Luttun et al.,
2000; Jackson, 2002): a) an excess of ECM proteolysis
can result in the removal or destabilization of those
critical epitopes able to guide migration of ECs; b) on
the other hand, an insufficient or inadequate ECM
proteolytic remodelling will again prevent migration of
ECs.
3.3 EC proliferation, three dimensional organization and
branching of new vessels
ECs will start then to proliferate in response to a
number of mitogenic stimuli (see Figs. 2C, 3) including
VEGF, basic and acidic FGF, hepatocyte growth factor
(HGF) and TGFα and TGFß. The literature suggests that
the most relevant stimulus is represented by VEGF
released by ECs themselves, as well as by a number of
neighbouring cells that for liver parenchyma after partial
hepatectomy, or in CLDs, are represented by hepatocytes
and hepatic stellate cells (HSC, which in normal liver
have been described to behave also as liver specific
pericytes), with kupffer cells and leukocytes possibly
making an additional contribution (Medina et al., 2004).
VEGF acts mainly on cells expressing VEGF type 1
(VEGFR-1) and type 2 (VEGFR-2) receptors (also
known as Flt-1 and Flk-1, respectively). Additional
positive stimuli for EC proliferation are provided by
cytokines, certain chemokines (others may exert the
opposite effect), hormones and lipid mediators whereas
the list of negative mediators able to inhibit EC
proliferation include interferon ß, antithrombin III,
platelet derived factor 4, leukaemia inhibiting factor,
with angiostatin and endostatin being the most effective
peptides in suppressing ECs proliferation (Carmeliet,
2003). 
Once EC proliferation is switched on in an ordered
manner, other steps, signalling pathways and mediators
are required for three-dimensional organization of
nascent vessels and for their conversion into mature
vessels in order to establish a functional vascular
network (Fig. 2C,D). The first step is represented by the
formation of a lumen in the nascent vessel that, together
with its diameter and length, is mainly affected by the
action of VEGF, Ang1 and integrins αvß3 and αvß5,
whereas thrombospondin has been suggested to act as a
major antagonist of this angiogenic step. Three
dimensional organization of an efficient vascular
network of vessels of uniform size additionally requires
a carefully orchestrated intervention of mediators and
activation of signalling pathways, resulting again in cell
proliferation and migration, as well as in the organized
branching of new vessels (mainly regulated by ephrins
and neuropilins) and in MMPs- and TIMPs-regulated
deposition of ECM components and formation of
basement membrane. 
3.4 Vessel maintenance, growth and stabilization versus
vessel regression
Conversion of nascent vessels into mature and
stabilized vessels now requires the progressive
association of pericytes or pericyte-like cells to newly
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Fig. 3. Angiogenesis as a
dynamic process: major
molecules involved and their
role.
formed vessels (Carmeliet, 2003; Jain, 2003), a crucial
event that also offers a significant contribution in
regulating EC proliferation, migration, survival,
differentiation, vascular branching, blood flow and
vascular permeability. In this setting a crucial role in the
stabilization of nascent vessels is provided by platelet-
derived growth factor (PDGF)-BB and its related
receptor ß-subunit (PDGFR-ß). PDGF-BB, mainly
released by ECs, contributes to recruit PDGFR-ß
positive mesenchymal cells or progenitors to nascent
vessels, leading also to their proliferation (Fig. 2D).
Lack of recruitment of mural cells to nascent vessels can
deeply affect vessel formation, resulting in more fragile,
larger and permeable vessels and then in bleeding,
decreased perfusion and hypoxia (Hellström et al., 2001;
Jain, 2003). Once recruited to nascent vessels
mesenchymal cells or progenitors can be differentiated
into pericytes by TGFß1, which is also fundamental in
sustaining deposition of ECM components. However,
the most important scenario for vessel stabilization is
represented by interactions between pericytes and ECs
of nascent vessels. Recruited pericytes start to release
Ang1 that interacts with the corresponding receptor Tie-
2 expressed on ECs, an event that tightens vessels by
affecting junctional molecules and by further promoting
interactions between ECs and mural cells (Jain, 2003),
possibly acting as a molecule facilitating ECs adhesion
mediated by integrins (Carlson et al., 2001). However,
one should remember that an excess of Ang1 can result
in the formation of too tightened vessels, preventing
further sprouting and even blocking angiogenesis.
An interesting role is the one played by Ang2, which
can activate Tie-2 in some cells and block it on others.
Although some studies have proposed a pro-angiogenic
role for Ang2 (for example in the heart by synergizing
with VEGF), it is established that when a lack of pro-
angiogenic signals occurs (including VEGF, PlGF,
PDGF-BB, Ang1) and/or an excess of angiogenic
inhibitors (thrombospondin, interferon ß and others) is
present in the microenvironment, Ang2 may induce cell
death of ECs and sustain vessel regression (Carmeliet,
2003, 2004). 
4. Angiogenesis and the liver 
Physiological and pathological angiogenesis have
been clearly identified in the following conditions: a)
during liver regeneration after acute liver injury or after
partial hepatectomy; b) in ischemic conditions; c) during
chronic inflammatory and fibrogenic liver diseases; d) in
hepatocellular carcinoma and in metastatic liver cancers
(Medina et al., 2004). 
Hepatic angiogenesis proceeds with steps and
molecular mechanisms that mostly overlap with those
just described in the previous paragraph. However, as
already pointed out by Medina et al. (2004), liver
angiogenesis is likely to be significantly affected by a
number of liver parenchyma peculiarities. First, the liver
is a peculiar organ characterized by the existence of two
different kinds of microvascular structures: a) large
vessels lined by a continuous endothelium lying on a
standard basement membrane, such as portal vessels
(portal veins, hepatic arterioles) and centrilobular veins;
b) liver sinusoids that are lined, in normal conditions, by
fenestrated and discontinuous ECs. Second, Camenisch
and coworkers (2002) have described the existence of a
liver derived angiopoietin-like peptide defined as
ANGPTL3; this peptide is unable to bind to Tie2
receptor but can bind αvß3 integrin, inducing haptotactic
endothelial cell adhesion and migration and stimulated
signal transduction pathways characteristic for integrin
activation, including phosphorylation of Akt, activation
of mitogen-activated protein kinase and focal adhesion
kinase. However, although ANGPTL3 has been shown
to operate as a potent pro-angiogenic peptide both “in
vivo” and “in vitro”, no data are available at present on
its role in either physiological or pathological liver
angiogenesis. 
Last, but not least, the unique and heterogenous
phenotypic profile and functional role of hepatic stellate
cells (HSCs): these peculiar cells are also regarded as
liver specific pericytes in normal liver (Friedman,
2008a) but their role in modulating angiogenesis may
differ from the role attributed to microcapillary pericytes
(Lee et al., 2007). As will be emphasized later in this
review, this is likely to occur mainly in pathological
conditions, such as during fibrotic progression of CLDs,
where myofibroblast-like cells (MFs) originating from
activated HSC (HSC/MFs) play a major pro-fibrogenic
role. The scenario is even more complex if one considers
that hepatic MFs constitute a heterogenous population of
pro-fibrogenic, highly proliferative and contractile cells
that may also originate from portal (myo)fibroblasts,
bone marrow-derived stem cells and, possibly, also from
hepatocytes and or cholangiocytes through a process of
epithelial to mesenchymal transition (Friedman, 2008b;
Parola et al., 2008). 
4.1 Physiological hepatic angiogenesis
Most reliable data have been obtained by studies
designed to investigate revascularization after
experimental partial hepatectomy (PH), which is
considered the most appropriate model to investigate
physiological hepatic angiogenesis. Hepatic
physiological angiogenesis was well reviewed by
Medina and coworkers some years ago (Medina et al.,
2004 and references therein) and here only major
specific events will be summarized as follows:
a) After two/third PH, the first relevant biologic
event is represented by an immediate and strong
proliferative response of parenchymal cells (usually with
two peaks of DNA synthesis at approx. 24 and 48 hrs),
mainly sustained by TGFα released by hepatocytes and
HGF released by non-parenchymal cells; this early
proliferative response involves mainly hepatocytes in the
periportal areas and this is crucial since it leads to the
formation in the same areas of avascular (i.e., hypoxic)
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clusters of hepatocytes.
b) Hepatocytes of these periportal clusters respond
to hypoxic conditions by up-regulating transcription of
VEGF within 48-72 hrs from PH; VEGF is then released
in a paracrine fashion and can act on all cells in which
the expression of VEGF receptors type 1 and 2 has been
detected, starting from 72 hrs and persisting for several
days, including arteriolar and sinusoidal ECs as well as
HSCs. Accordingly, reconstitution of sinusoids by ECs
initiate then in the same periportal areas
c) VEGF, which may also concur to sustain
hepatocyte proliferation, has also been reported to prime
ECs to express a number of growth factors that may
contribute to prevent hepatocyte injury, as well as to
exert its effects (proliferation, synthesis of ECM) on
HSCs. Finally, as will be recalled later, VEGF can also
be released by HSCs exposed to hypoxic conditions. 
5. Angiogenesis in chronic liver diseases
characterized by persisting inflammation and
progressive fibrogenesis: “in vivo” evidence
Chronic liver diseases are usually characterized by
reiteration of liver injury due to a number of aetiological
conditions, including chronic infection by viral agents
(mainly by hepatitis B and C viruses) as well as
metabolic, toxic/drug-induced (with alcohol
consumption being predominant) and autoimmune
causes. This is known to result in persisting
inflammation and progressive fibrogenesis, with chronic
activation of the wound healing response representing a
major driving force for progressive accumulation of
ECM components, eventually leading to liver cirrhosis
and hepatic failure. Other mechanisms sustaining
fibrogenic progression of CLDs include oxidative stress
and redox signalling, derangement of epithelial -
mesenchymal interactions and, as emerging evidence
suggests, the process of epithelial to mesenchymal
transition (Parola and Robino, 2001; Friedman, 2003,
2004, 2008b; Bataller and Brenner, 2005; Novo and
Parola, 2008; Parola et al., 2008). Although different
patterns of fibrosis progression have been reported to
exist that may depend on the specific aetiology, as well
as the prevailing pro-fibrogenic mechanism (Pinzani and
Rombouts, 2004; Parola et al., 2008), cirrhosis is indeed
currently envisaged as an advanced stage of fibrosis that
is typically characterized by a common scenario which
includes the formation of regenerative nodules of
parenchyma surrounded and separated by fibrotic septa
and associated with significant changes in angio-
architecture. 
As mentioned in the introductory remarks, it is a
common feeling that angiogenesis as a process, when
occurring during hepatic chronic wound healing and
fibrogenesis, may significantly contribute to disease
progression (Friedman, 2004, 2008b; Medina et al.,
2004; Lee et al., 2007; Parola et al., 2008). This
hypothesis of course relies first on the established
concept that angiogenesis is a major process involved in
wound healing, being integrated with the inflammatory
process (Carmeliet, 2003). Moreover, it is well known
that a common finding in human cirrhotic livers,
irrespective of the aetiology, is represented by enhanced
vascular remodelling (i.e., a condition that by itself
suggests involvement of pathological angiogenesis). If
angiogenesis in chronic inflammatory and fibrotic liver
injury is concerned, one has also to remember that
formation of fibrotic septa, as well as capillarization of
sinusoids, the latter due to early deposition of fibrillar
ECM in the space of Disse, can result in an increased
resistance to blood flow and oxygen delivery (i.e., the
premises for hypoxia), irrespective of aetiology. This is
relevant since, as previously suggested, hypoxia is by far
the main and most obvious stimulus for angiogenesis in
any organ or tissue, with transcription of hypoxia-
sensitive pro-angiogenic genes usually being modulated
through HIFs. 
In addition, from a general point of view, one has to
emphasize the well known relationships between the
inflammatory process and angiogenesis. Indeed, during
the course of CLDs the inflammatory response gains the
role of a dynamic state relevant for the progression of
fibrogenesis towards the end-point of cirrhosis
(Friedman, 2004, 2008b). If relationships between
inflammation and angiogenesis are concerned, it is well
known that several mediators of the inflammatory
response may stimulate other cells in the surrounding
microenvironment to express VEGF and other pro-
angiogenic factors (Carmeliet, 2004). Other cytokines
and mediators, known to be overexpressed during the
condition of chronic inflammatory liver injury, have
been suggested to play a role in the development of
angiogenesis, including HGF, NO and PDGF (Medina et
al., 2004). Moreover, one should consider that: a) neo-
vessels are likely to significantly contribute to
perpetuation of the inflammatory response by expressing
chemokines and adhesion molecules promoting the
recruitment or inflammatory cells; b) angiogenesis, early
in the course of a CLD, may even contribute to the
transition from acute to chronic inflammation (Jackson
et al., 1997).
After these general concepts, we will analyze in the
following sections the relationships between
angiogenesis, inflammation and progressive fibrogenesis
on the basis of most significant “in vivo” and “in vitro”
published literature data and, where possible, offer
“ready to use” overall messages.
5.1 Angiogenesis in clinical and experimental conditions
of CLDs
A first message to be delivered is straightforward:
unequivocal evidence of angiogenesis, including
overexpression of pro-angiogenic cytokines and related
receptors, has been detected in all relevant clinical
conditions of CLDs, irrespective of aetiology, as well as
in the most widely used experimental animal models of
CLDs (Medina et al., 2004; Lee et al., 2007) and an
1329
Angiogenesis in chronic liver diseases
overview of available data on cellular source and/or
localization of angiogenic molecules in CLDs is offered
in Figure 4. Moreover, in most pathological conditions
angiogenesis and fibrogenesis seem to develop in
parallel during progression towards cirrhosis, although
for obvious reasons the most detailed studies have been
performed on experimental models (Rosmorduc et al.,
1999; Corpechot et al., 2002a; Yoshiji et al., 2003;
Kitade et al., 2006; Novo et al., 2007; Tugues et al.,
2007; Taura et al., 2008; Moon et al., 2009; see also
sections from 5.2 to 5.5). Apart from those events that
may be considered to be in line with the general scheme
of angiogenesis, a number of findings related mainly to
chronic viral hepatitis and autoimmune diseases deserve
further comment. 
Chronic infection by HBV and HCV
Liver biopsies from patients affected by chronic
viral hepatitis have shown the presence of ECs and
neovessels in the form of capillary structures found in
inflamed portal tracts (García-Monzón et al., 1995;
Mazzanti et al., 1997; Medina et al., 2004). All major
angiogenic molecules have been found to be over-
expressed in these patients, including VEGF and HGF
(Okajima et al., 1997; Okano et al., 1999; Shimoda et al.,
1999; Medina et al., 2003a); PDGF has been found
overexpressed in periportal inflammatory cells,
sinusoidal and perisinusoidal cells (Pinzani et al., 1996;
Ikura et al., 1997). If overexpression of VEGF and
PDGF is likely to result in established pro-angiogenic
effects for these growth factors, such as migration and
proliferation of ECs for VEGF, or stabilization of
nascent vessels for PDGF, HGF, which is a well known
potent inducer of angiogenesis (Bussolino et al., 1992;
Grant et al., 1993), has been described to stimulate
proliferation and migration of ECs either by direct
actions on ECs or through indirect paracrine stimulation
of neighbouring cells such as SMCs to express VEGF
(Van Belle et al., 1998; Medina et al., 2003a) . 
Interestingly, it has been proposed for patients
affected by chronic viral hepatitis that some selected
viral proteins may have a pro-angiogenic role. A well
characterized example is represented by HBV-related X
protein, which has beenshown to be involved in
disruption of inter-endothelial junctions by operating
through a src-kinase-dependent signalling pathway
(Lara-Pezzi et al., 2001), as well as in the up-regulation
of inducible nitric oxide synthase (iNOS) through
involvement of nuclear factor - κB (NF-κB)
transcription factor (Majano et al., 2001). Indirect
evidence also suggests that the same viral protein may
be able to up-regulate in hepatocytes membrane-type
MMP (MT-MMP) expression, and then MMP-2
activation, through mechanisms requiring
cyclooxygenase 2 activation (Lara-Pezzi et al., 2002);
this event may favour angiogenesis (see previous section
3.2) as well as hepatocyte invasion. 
Another interesting finding (see also section 5.5 on
the role of MFs in angiogenesis for more details)
detected in biopsies from chronic HCV patients is
represented by the fact that tiny and incomplete
developing fibrotic septa show the existence, at their
leading or lateral edge, of MF - like α-smooth muscle
actin (α-SMA) positive cells that are also positive for
VEGF, Ang-1 and Tie-2 (Novo et al., 2007). This
scenario, which is homologous to the one detected in the
cirrhotic rat livers following chronic CCl4 treatment,
1330
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Fig. 4. Expression of angiogenic molecules and their receptors by
different hepatic cell populations involved in chronic liver diseases.
consistently differs from images observed for larger and
more mature septa, where α-SMA positive cells (i.e.,
MFs) are distinct from cells positive for VEGF
(hepatocytes and ECs) or Flk-1 and Tie-2 (mainly ECs).
As will be emphasized later, these findings may reflect
two different phases of angiogenesis during chronic
wound healing in chronic HCV patients. 
Autoimmune chronic liver diseases
Evidence for angiogenesis was detected in biopsies
from patients affected by either primary biliary cirrhosis
(PBC) or autoimmune hepatitis as formation of tubule-
like structures (i.e., neovessels) by ECs positive for CD-
31 and vascular endothelial-cadherin (Medina et al.,
2003b, 2004, 2005). These neovessels were located,
particularly for PBC, mainly in portal areas in
association with inflammatory infiltrate (Medina et al.,
2005). 
Where PBC is concerned, enhanced expression of
angiogenic molecules like VEGF, Ang-1, Ang-2, Tie-2
and endoglin has been also characterized in PBC
patients. Moreover, additional indirect evidence
suggesting the existence of angiogenesis in PBC was in
the report that ECs are positive for fibronectin and
laminin (known to be involved in the regulation of
angiogenesis) and, interestingly, that ECs of the
peribiliary plexus are positive for ß1 integrins
(Yasoshima et al., 2000). 
It should be noted, in this connection, that some
authors have reported for autoimmune diseases like
PBC, primary sclerosing cholangitis (PSC) and
autoimmune hepatitis, a tendency to develop vasopenia
and a decrease in peribiliary capillary plexus
(Washington et al., 1997; Matsunaga and Terada, 1999).
This scenario was attributed to destruction of vascular
structures by autoimmune mechanisms, similar to the
process undergone by bile ducts in PBC and PSC;
vessels (including newly formed capillaries) might also
be destroyed during the scarring phases of the disease.
However, as proposed by Medina and coworkers
(Medina et al., 2004, 2005), this apparent controversy
might be simply related to the different temporal
dynamics of neoangiogenesis and autoimmune
destruction of vascular structures in PBC. 
5.2 Hypoxia and pathological angiogenesis in CLDs
Another major message offered mainly by
experimental models of CLDs is that overexpression of
the prototype pro-angiogenic cytokine VEGF is usually
found in hypoxic areas, according to the rational
hypothesis that hypoxia may represent the major
stimulus for hepatic angiogenesis. Indeed, animal
models offer the unique opportunity to use antibodies
rised against pimonidazole adducts to identify hypoxic
areas: pimonidazole and other related nitroimidazole
derivatives have been described to bind macromolecules
in cells exposed to low oxygen levels, and pimonidazole
binding has been shown to be effective in assessing
changes in hepatic tissue oxygenation (Arteel et al.,
1995, 1997). 
VEGF expression in normal liver, as well as its
colocalization with pimonidazole adducts or nuclear
HIF1α is mostly limited, as already mentioned in section
2, to a few hepatocytes constituting the first row around
centrilobular vein (Arteel et al., 1995; Rosmorduc et al.,
1999; Corpechot et al., 2002a; Gaudio et al., 2006;
Bozova and Elpek, 2007; Tugues et al., 2007). An
apparent exception to this rule has been reported for
cholangiocytes that, at least in one study, seem to
express VEGF even in normal conditions (Gaudio et al.,
2006). 
Historically, the first report of a close association
between hypoxic areas, VEGF expression and then EC
proliferation and angiogenesis in conditions of
experimental CLDs was provided for the model of bile
duct ligation (Rosmorduc et al., 1999). Most, if not all
positive immunostaining for VEGF was detected in
hepatocytes with a percentage of positive parenchymal
cells ranging from 95% at 2 weeks after BDL to approx.
100% at the time of established biliary cirrhosis. In this
study no apparent immunopositive stain for VEGF was
detected in either hepatic stellate cells or cholangiocytes.
This scenario differs from that reported by others
concerning HSC and HSC/MFs for other conditions of
liver injury and CLDs (see later), as well as from that
described in a study using the same model of BDL
(Gaudio et al., 2006) showing that cholangiocytes of the
bile ductular reaction are able to express VEGF as well
as VEGF receptors type 2 (Flk-1) and 3, suggesting a
possible mitogenic effect for VEGF to sustain both
proliferation of cholangiocyte (paracrine/autocrine
effect) and ECs of microcapillary peribiliary plexus
(paracrine effect). 
The colocalization of hypoxic areas with VEGF
overexpression and/or the association between VEGF
expression and progression of fibrogenesis was then
confirmed by the same group using the diethyl-
nitrosamine (DEN) model of fibrosis (Corpechot et al.,
2002a), as well as by others employing the model of
CLD induced by chronic treatment with CCl4 (Yoshiji et
al., 2003; Novo et al., 2007; Tugues et al., 2007) or by
feeding a choline-deficient and aminoacid-defined diet
able to induce in rats a NAFLD, developing in time into
NASH and significant fibrosis (Kitade et al., 2006). In
most of these studies (see later sections 6.2 and 6.3 for
more details) parallel “in vitro” and “in vivo”
experiments were starting to outline that not only
hepatocytes, but also HSC and/or HSC/MFs, particularly
under hypoxic conditions, may be able to express both
angiogenic cytokines as well as related receptors. Of
relevance, in a study very recently published on-line
(Moon et al., 2009), the strict relationships between
hypoxia, angiogenesis, inflammation and fibrogenesis
have been unequivocally confirmed by using liver
conditional HIF-1α-deficient mice that were subjected to
BDL: in these mice, where a very significant decrease in
1331
Angiogenesis in chronic liver diseases
collagen type I and α-SMA transcripts and protein
levels, as well as of transcripts for PDGF and
plasminogen activator inhibitor-1 (PAI-1) was detected,
vs respective wild type mice in which the typical
scenario of biliary type fibrosis and cirrhosis was
associated to early and sustained up-regulation of HIF-
1α. 
Before leaving this section, another relevant study,
able to further emphasize the role of hepatic hypoxia
during the development of CLDs, should be at least
mentioned (Corpechot et al., 2002b). Some years ago it
was reported that hypoxia can negatively affect
hyperplastic reponse of hepatocytes by at least two
additional mechanisms: a) by down-regulating the ability
of HSC to express HGF, the most potent mitogenic
stimulus for parenchymal cells; b) by rapidly inhibiting
c-met expression in hepatocytes. It is clear that these two
mechanisms are likely to significantly contribute to
depress liver regeneration during chronic liver injury.
5.3 Pathological angiogenesis as a potential therapeutic
target
On the basis of concepts and data presented in the
previous sections and chapters, an obvious consequence
of the proposed relationships between angiogenesis and
chronic wound healing and fibrogenesis (i.e.,
angiogenesis may contribute to disease progression)
should include two main implications: a) a careful, non-
invasive, detection of marker molecules involved in
pathological angiogenesis may offer a way to monitor
both disease progression as well as the response to the
therapy; b) pathological angiogenesis may become a
potential therapeutic target in patients affected by CLDs. 
Concerning the first point, we are still far from
having enough reliable data to be translated to clinically
relevant conditions. To our knowledge just a single study
on 36 patients affected by chronic hepatitis C (vs 15
healthy controls) has provided a serious attempt to
correlate circulating levels of molecules involved in the
angiogenic process with disease progression and efficacy
of standard combination therapy based on pegylated
interferon alfa-2b (IFN-α2b) and ribavirin (Salcedo et
al., 2005). In this study serum levels of VEGF, Ang-2
and soluble Tie-2 (sTie-2) were determined before and
after therapy and the authors reported that patients
affected by chronic hepatitis C (CHC) showed elevated
baseline VEGF and Ang-2 levels; moreover, after
therapy both angiogenic factors were significantly
decreased, whereas antiangiogenic sTie-2 was increased,
results that were interpreted as evidence of a shift toward
an “anti-angiogenic” profile of serum markers in CHC
patients responding positively to the therapy.
As far as second implication is concerned, available
data on experimental animal models of CLDs
unequivocally indicate that antiangiogenic therapy is
effective in preventing progressive fibrogenesis. The
first study to deal with experimental antiangiogenic
therapy for CLDs was based on “in vivo” administration
of the semisynthetic analogue of fumagillin TNP-470
(Wang et al., 2000). This potent antiangiogenic inhibitor
was used because of its very low toxicity (Ingber et al.,
1990; Kusaka et al., 1991), the documented experimental
ability to effectively inhibit growth of hepatocellular
carcinoma (HCC) and of hepatic metastasis (Tanaka et
al., 1995; Shishido et al., 1996; Ikebe et al., 1998) and,
more relevant, the ability to also inhibit proliferation of
mesangial cells and vascular SMCs (Haraguchi et al.,
1997; Koyama et al., 1996). Repetitive subcutaneous
injection of TNP-470 to rats submitted to either the
CCl4-or diethylnitrosamine-induced liver fibrosis
resulted in a very significant reduction of ECM
deposition. Data obtained for CCl4-dependent chronic
liver injury also indicated a sharp reduction in the
number of α-SMA positive cells and of the
bromodeoxyuridine (BrdU) positive cells. Indeed, in
vitro experiments performed on primary culture of rat
HSC showed that TNP-470 was able to inhibit
proliferation of these cells by blocking cell cycle
transition from G1 to S phase, as well as to inhibit their
activation (Wang et al., 2000). 
Another elegant and effective antiangiogenic
approach was obtained by “in vivo” administration to
BalbC mice, chronically treated with CCl4, of antibodies
able to neutralize either VEGFR-1 (Flt-1) and/or
VEGFR-2 (Flk-1) (Yoshiji et al., 2003). Once again, this
treatment was able to significantly inhibit angiogenesis,
the number of α-SMA positive cells and the
development of fibrosis. Two other major findings or
concepts were provided by this study: a) VEGF
expression (mainly the alternative mouse splicing VEGF
genes leading to VEGF120 and VEGF164) was a
prerequisite for murine fibrogenesis since neutralizing
antibodies were administered after two weeks of
treatment; b) although combination treatment with both
antibodies was slightly more effective, the most relevant
anti-fibrotic effect was by far observed using the anti-
VEGFR-2 antibody, suggesting “in vivo” predominance
of VEGF interaction with Flk-1 to mediate angiogenesis
during chronic liver injury.
The latter finding was remarked by other
observations provided by Fernandez and colleagues
(Fernandez et al., 2004, 2005) who, by again using the
antibodies able to neutralize VEGFR-2 in a model of
portal hypertensive rats, were also able to correlate
VEGF expression and related angiogenesis to the
development of porto-systemic collateral vessels and of
hyperdynamic splancnic circulation. These findings (see
also Morales-Ruiz and Jimenez, 2005; Morales-Ruiz et
al., 2005) are of intrinsic relevance because they suggest
that the increase in portal blood flow, which is an
important contributor to portal hypertension, depends
not only on vasodilation, but also on the enlargement of
the splancnic vascular tree caused by angiogenesis. 
A more recent antiangiogenic approach (Tugues et
al., 2007) has taken advantage of the multitargeted
tyrosine kinase receptor inhibitor Sunitinib (SU11248).
The rationale to use this indolinone derivative relied on
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the fact that it was designed as a drug, having a broad
selectivity for several receptor tyrosine kinases (Smith et
al., 2004), with an already established antitumour and
antiangiogenic effects in clinical trials for cancer
treatment (Abrams et al., 2003; Deeks and Keating,
2006). In particular, the antiangiogenic effect of
Sunitinib is attributable at least to inhibition of VEGF
and PDGF receptors which, as reported in section 3, are
both essential for angiogenesis (Carmeliet, 2003;
Armulik et al., 2005). Moreover, it is well known that
PDGF (particularly PDGF-BB and its related receptor ß
subunit or PDGFR-ß) represent the most potent
mitogenic and chemotactic agent for HSC and HSC/MFs
(Pinzani et al., 1989; Pinzani and Marra, 2001;
Friedman, 2008a,b). In the study by Tugues and
coworkers, where cirrhosis progression in the liver of
rats chronically treated with CCl4 was associated with
an increased expression of VEGF, Ang-1, Ang-2 and
PlGF, as well as of hepatic and splanchnic
vascularization, the treatment of cirrhotic animals with
Sunitinib resulted in a significant decrease of a number
of inter-related pathological events, including hepatic
vascular density, inflammatory infiltrate, abundance of
α-SMA positive mesenchymal cells, ECM deposition
and portal pressure. Parallel “in vitro” experiments
performed on the human immortalized HSC cell line
LX-2 were also able to show that Sunitinib was indeed
affecting the response of these cells to PDGF-BB. 
The experimental antiangiogenic approaches
previously reported were all mainly directed at blocking
the action of VEGF, widely accepted as the most potent
pro-angiogenic cytokine in both physiological and
pathological conditions. However, in the last two years
“in vivo” studies from different laboratories have
outlined that the proangiogenic role of HSC (see section
6.2 for more details) can also be mediated by the release
of Ang-1, as seen in either experimental fibrotic and
cirrhotic livers or in biopsies from HCV cirrhotic
patients (Novo et al., 2007; Taura et al., 2008). Both
laboratories reported that in cirrhotic livers
immunostaining for Ang-1 was colocalized with α-
SMA, a marker of myofibroblast-like cells. In
experimental animals subjected to BDL or chronically
treated with CCl4 a parallel increase of CD31 and Ang-1
mRNA was reported, suggesting a significant angiogenic
role of Ang-1 (Taura et al., 2008). This hypothesis was
confirmed by the same group by injecting mice under
BDL or chronic CCl4 treatment with an adenovirus
expressing soluble Tie-2 (AdsTie-2, the receptor for
Ang-1, then able to block angiopoietin signalling), a
procedure that resulted in a significant prevention of
both angiogenesis and fibrosis. 
5.4 The “in vivo” role of other mediators on angiogenesis
in CLDs: the pro-angiogenic action of leptin and PDGF
Several peptide mediators other than VEGF, Ang-1
and HGF are likely to be involved in hepatic
angiogenesis associated with the fibrogenic progression
process in CLDs. Here we would like to focus attention
on the “angiogenic” activity of a limited number of
polypeptide mediators of ascertained relevance in
progressive fibrogenesis, like leptin and PDGF. 
Leptin as an “in vivo” pro-angiogenic mediator
Leptin is a circulating peptide hormone, the product
of the obese (ob) gene, which is mainly produced by
adipose tissue in relation to its mass (Ahima and Osei,
2004). Although originally described mainly as a satiety
factor, leptin is now recognized as a pleiotropic peptide
able to modulate immune function, fertility, bone
formation and wound healing (Huang and Li, 2000;
Faggioni et al., 2001). Pertinent to this review, leptin is
also able to modulate the response to liver injury (Yang
et al., 1997; Faggioni et al., 2000) and has been reported
to act as a pro-fibrogenic mediator on HSC and
HSC/MFs (Marra, 2002; Friedman, 2008b). The
potential role of leptin as a hepatic pro-angiogenic
peptide was first reported in a study showing that human
HSC/MFs were able to respond to leptin (see details in
section 6.2) by up-regulating both VEGF and Ang-1
expression, as well as the pro-inflammatory chemokine
monocyte chemoattractant protein 1 or MCP-1 (Aleffi et
al., 2005). More relevant, in the same study positive
immunostaining for the leptin receptor ObR was found
to colocalize with VEGF and α-SMA in fibrotic rat
livers after chronic CCl4 administration. 
The profibrogenic action of leptin has been mainly
involved in the pathogenesis of non-alcoholic steato-
hepatitis (NASH), a very common hepatic condition in
western countries, mostly found in obese and/or diabetic
patients carrying metabolic syndrome, and potentially
able to progress towards cirrhosis and even HCC
(Angulo, 2002; Marra, 2002; Tilg and Hotamisligil,
2006; Parekh and Anania, 2007). Along these lines, in
order to study the role of angiogenesis in NASH a
Japanese group (Kitade et al., 2006) administered
Zucker rats, animals that naturally develop leptin
receptor mutations, and their lean littermates the
steatogenic choline-deficient and aminoacid defined
(CDAA) diet. Although both Zucker and littermate rats
similarly developed a marked steatohepatitis, the most
relevant message from the study was that progression to
fibrosis and cirrhosis was only seen in lean littermate
rats, which is the animal able to express normal leptin
receptors. Lean littermate rats exposed to CDAA diet,
but again not Zucker rats, were also the only animals in
which progressive fibrogenesis was associated with a
parallel increase in VEGF expression and hepatic
neovascularisation, with CD31 neovessels mostly
located along fibrotic septa. 
Results from the two studies cited (Aleffi et al.,
2005; Kitade et al., 2006) indeed suggest that leptin,
possibly by inducing HSC/MFs to express angiogenic
cytokines, may contribute to regulate neovascularization
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in NASH favouring fibrosis progression. 
PDGF and hepatic angiogenesis
As already outlined in section 3, PDGF has a well
established pro-angiogenic role that is mainly related to
the ability to recruit pericytes and mesenchymal cells to
neovessels in order to favour their stabilization. In the
case of liver, this is likely to involve recruitment of HSC
that have been described to act as liver specific pericytes
and to be extremely sensitive to both mitogenic and
chemotactic action of PDGF (Pinzani and Marra, 2001;
Carmeliet, 2003; Lee et al., 2007; Friedman, 2008b;
Parola et al., 2008). In a very recent paper Semela and
coworkes, using the PDGF-R inhibitor Imatinib and a
number of elegant experimental approaches, nicely
outlined that PDGF is indeed able to promote an
angiogenic phenotype of HSC by stimulating a
downstream signalling also involving ephrin-B2, which
is fundamental in regulating the HSC-driven process of
vascular tube formation “in vitro”, as well as enhance
“in vivo” coverage of sinusoids (Semela et al., 2008).
These events are likely to significantly affect crucial
pericyte-mediated vascular functions like vascular
permeability and pressure regulation. 
6. Involvement of HSCs and HSC/MFs in liver
angiogenesis: the search for stimuli and
mechanisms 
In the previous paragraph a possible role for HSCs
and HSC/MFs (possibly also for other hepatic
myofibroblast-like cells originating from other cell
sources) in modulating angiogenesis has already
emerged from data and concepts provided by “in vivo”
studies. In the next few sections we would like to
propose that, on the basis of published literature data,
HSC in physiological angiogenesis and HSC/MFs during
pathological angiogenesis in CLDs represent an
hypoxia-sensitive and cyto- and chemokine-modulated
cellular crossroad between necro-inflammation,
angiogenesis and fibrogenesis. Along these lines, since
the pro-inflammatory and pro-fibrogenic role of HSC
and mainly of HSC/MFs is well established (Pinzani and
Marra, 2001; Bataller and Brenner, 2005; Friedman,
2008a,b; Parola et al., 2008) we will focus the analysis
on HSCs as liver specific pericytes and on the dual role
of HSC and HSC/MFs (as pro-angiogenic cells and as
target cells for angiogenic cytokines) in relation to
hepatic angiogenesis and vascular remodelling. 
6.1 HSCs as liver specific pericytes
A role for HSCs as specific liver pericytes was first
proposed more than fifteen years ago (Pinzani et al.,
1992) and indeed there are several features and findings
that support this concept and suggest a vasomotor
function for these cells. First, HSCs can express
phenotypic markers that are in common with other
pericytes, including desmin, glial fibrillary acidic protein
(GFAP), NG2 and, for activated cells, α-SMA (Geerts,
2001), and are known to respond to PDGF. Second,
these cells are located in a strategic anatomical site, the
space of Disse, and then in intimate contact with
sinusoidal ECs by means of their characteristic
perisinusoidal or sub-endothelial processes (Blomhoff
and Wake, 1991; Geerts, 2001). The processes of a
single HSC run along one or more adjacent sinusoids,
with secondary processes being able literally to encircle
the sinusoid in a cylindrical manner, making realistic the
hypothesis of cells able to regulate blood flow (i.e.,
vasomotor cells) by modulating sinusoidal diameter.
Along these lines, one should note that HSCs in normal
liver are reached by axonal processes of autonomic
nerve fibers that contain several vasoactive peptides
(substance P, neuropeptide Y, somatostatin and
calcitonin gene-related peptide). Third, several
laboratories have provided evidence indicating that
cultured HSC can respond to a number of vasoactive
agents, including a) those able to induce contraction, like
endothelin-1, angiotensin II, thrombin, vasopressin,
prostaglandin F2α, thromboxane A2, substance P,
platelet-activating factor (PAF) and adenosine; b) those
able to induce vasodilation, like NO, carbon monoxide,
prostaglandin E2 (PGE2), lipoPGE1 and adrenomedullin
(Geerts, 2001; Rockey, 2001 and references therein).
Even more relevant, several studies have provided
evidence indicating that HSCs can contract in situ in the
hepatic sinusoids (Rockey, 2001 and references therein).
Moreover, there is a general agreement that in the
scenario of CLDs, characterized by over-production of
ET-1 (with HSC/MFs actively contributing to this event)
and reduction of NO released by ECs, HSCs and
HSC/MFs may contribute to the increased intrahepatic
resistance and then the genesis of portal hypertension
(Rockey, 2001 and references therein). 
More recent data, described in the next sections,
have extended this concept and suggested a role for
HSC/MFs in sustaining angiogenesis and sinusoidal
remodelling in CLDs (Lee et al., 2007). 
6.2 HSCs and HSC/MFs as pro-angiogenic cells
The first findings suggesting that HSCs and
HSC/MFs may actively contribute to angiogenesis were
obtained no more than ten years ago by two different
laboratories using the experimental model of CCl4-
induced acute liver injury (Ankoma-Sey et al., 1998;
Ishikawa et al., 1999). These studies analysed in a time
dependent way recovery from acute liver injury and, by
taking advantage of morphological analysis or by
detecting transcripts for angiogenesis-related molecules,
both laboratories showed that VEGF expression was not
limited to ECs or hepatocytes but was also detectable in
mesenchymal cell types, particularly transiently
activated HSCs. In one of these studies (Ankoma-Sey et
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al., 1998) the authors showed that VEGF expression by
rat HSCs, as isolated at different times from CCl4
administration, was paralled by increased expression of
VEGF receptors Flt-1 and Flk-1; moreover, rat HSCs in
primary culture were shown to undergo increased
expression of VEGF in parallel with the process of
activation. 
Hypoxic conditions and the angiogenic role of
HSC/MFs
The latter concept (i.e., VEGF and related receptors
being overexpressed by activated HSCs or HSC/MFs)
was strengthened by findings coming from different
laboratories that, by using either rat (Ankoma-Sey et al.,
2000; Wang et al., 2004) or human (Aleffi et al., 2005;
Novo et al., 2007) HSC/MFs, were all able to show that
these cells, when exposed to hypoxic conditions, were
able to up-regulate transcription and release of VEGF in
a HIF-1α - dependent way. In T6 rat immortalized HSCs
(Ankoma-Sey et al., 2000) hypoxia was able to induce
all four different splice variants of VEGF described by
the literature (VEGF-120, -144, -164 and -188) with up-
regulation of VEGF expression being also mimicked by
the release of NO from NO-donors. Where VEGF
receptors are concerned, rat and human cells behaved in
a slightly different way following hypoxia, with human
cells up-regulating both major receptors (Flt-1 and Flk-
1) and rat cells responding mainly by up-regulating
VEGFR-1 (Flt-1). Exposure of human HSC/MFs to
hypoxic conditions also resulted in significant up-
regulation of Ang-1 and of the related receptor Tie2
(Aleffi et al., 2005; Novo et al., 2007); concerning Ang-
1, it should be noted that even in normoxic conditions
culture activated HSC are able to express this angiogenic
cytokine (Aleffi et al., 2005; Taura et al., 2008). 
Taken together, all the published data on cultured rat
and human HSC/MFs can be considered as fully
compatible with those reported “in vivo” (Rosmorduc et
al., 1999; Corpechot et al., 2002a; Yoshiji et al., 2003;
Novo et al., 2007; Taura et al., 2008; Tugues et al., 2008)
indicating that indeed hypoxic conditions represent an
effective stimulus for HSC/MFs to acquire a pro-
angiogenic phenotype, resulting in increased
transcription and release of VEGF and Ang-1. 
Along these lines, one should also consider a major
finding obtained some years ago, suggesting that
paracrine expression of VEGF by HSCs, as well as by
hepatocytes, may regulate the phenotype (i.e.,
fenestration and CD-31 expression) of liver sinusoidal
endothelial cells (DeLeve et al., 2004). 
Leptin as a pro-angiogenic mediator for HSC/MFs:
facts and mechanisms. 
As already discussed in section 5.4, leptin can
behave “in vivo” not only as a pro-fibrogenic agent, as
suggested by several studies on different animal models
(Honda et al., 2002; Leclercq et al., 2002; Saxena et al.,
2002), but also as a pro-angiogenic mediator, as
unequivocally shown by data obtained in Zucker and
lean littermate rats exposed to CDAA diet (Kitade et al.,
2006) and suggested by data obtained in fibrotic livers of
rats chronically treated with CCl4 (Aleffi et al., 2005).
Data obtained by analysing the action of leptin on
human HSC/MFs have clearly shown how this may
occur. The following concepts emerged from specifically
designed experiments (Aleffi et al., 2005): a) human
HSC/MFs respond to leptin by up-regulating VEGF and
Ang-1 as well as the pro-inflammatory chemokine MCP-
1; b) the action of leptin is possible because human
HSC/MFs are able to express functional receptors
(ObRs), with a detected specific increased
phosphorylation for ObRb receptor isoform; c) leptin,
following interaction with ObRs, stimulates several
signalling pathways and transcription factors, including
signal transducing and activator 3 (STAT3), NF-κB and,
as also shown by others (Saxena et al., 2004),
extracellular regulated kinases (ERK1/2) and c-Akt; 4)
interestingly, leptin was also able to recruit and stabilize
HIF-1α, leading to its nuclear translocation in a ERK1/2
and PI3-K-dependent fashion. 
6.3 HSC/MFs as a profibrogenic target for the action of
angiogenic mediators. 
In this final section we would like to review the
available literature data concerning an obvious
implication of what we reported in the previous sections
and paragraphs. Activated HSCs (then HSC/MFs) shows
“in vivo” as well as “in vitro” the ability (for ex.
responding to hypoxia and leptin) to up-regulate
expression of both VEGF and Ang-1, as well as, likely,
to release these mediators in the extracellular
microenvironment; at the same time (Novo et al., 2007;
Taura et al., 2008) these cells can also express receptors
for VEGF and Ang-1 (Flk-1 and Tie-2, respectively),
again following exposure to hypoxia. The question then
is whether this response of HSC/MFs is solely related to
angiogenesis or if it may also contribute to further
sustain (in a paracrine/autocrine way) the profibrogenic
attitude of HSC/MFs. In other words, are VEGF and
Ang-1 able to sustain pro-fibrogenic phenotypic
responses o HSC/MFs and, possibly, of all hepatic MFs?
A number of experimental studies have addressed this
point and here major data are summarized. 
VEGF as a mitogen for HSC/MFs
The first phenotypic response analyzed by
researchers in the field was the ability of angiogenic
cytokine to affect proliferation of HSC/MFs. A positive
answer has been documented for VEGF in activated rat
HSC/MFs by different laboratories (Ankoma-Sey et al.,
1998; Olaso et al., 2003; Yoshiji et al., 2003). In two of
these studies it was reported that stimulation of
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proliferation was significant only if cells were plated on
a substrate of collagen type I, but not on other substrates
resembling the normal sub-endothelial matrix of the
liver (Ankoma-Sey et al., 1998; Yoshiji et al., 2003).
Indeed, when human HSC/MFs were cultured just on
plastic the mitogenic effect of VEGF could not be
detected (Novo et al., 2007), and this may also explain
another negative report for VEGF mitogenic action on
rat HSC/MFs (Mashiba et al., 1999). Interestingly, it was
also reported that VEGF - induced proliferation was
significantly increased by concomitant treatment with
bFGF (Ankoma-Sey et al., 1998). In the study by Olaso
and coworkers, increased proliferation of activated
HSC/MFs was found when these cells were exposed to a
conditioned medium obtained from a melanoma cell
line, which was found to result in up-regulation of
VEGF transcription in HSC/MFs. This event was
enhanced by hypoxia and blocked by using antibodies
neutralizing VEGF (Olaso et al., 2003). 
No other pro-angiogenic cytokine has been reported
to be able to affect proliferation of HSC/MFs, as our
personal experience on human HSC/MFs exposed to
recombinant Ang-1 has also confirmed (unpublished
results).
VEGF as a stimulus for ECM deposition but
interfering with contraction.
The next step was to analyse whether angiogenic
cytokines were able to affect synthesis of ECM proteins.
Once again, positive results were limited to VEGF that
significantly up-regulated pro-collagen type I mRNA
and protein synthesis (Olaso et al., 2003; Yoshiji et al.,
2003). The same conclusion can be reasonably proposed
for data provided by Corpechot and coworkers
(Corpechot et al., 2002a) who were able to show up-
regulation of procollagen type I synthesis in rat
HSC/MFs exposed to hypoxia, a procedure also resulting
in VEGF up-regulation and release in the medium.
However, VEGF ability to up-regulate procollagen type
I was not confirmed by others when using either rat
HSC/MFs (Mashiba et al., 1999) or human HSC/MFs
(Novo E and Parola M, unpublished results). Moreover,
once again, Ang-1 was found to be ineffective on pro-
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Fig. 5. In vivo localization of VEGF receptor type II or Flk-1 in a human cirrhotic liver from a HCV chronic patient. Indirect immunofluorescence on
cryostat sections from cirrhotic liver of Flk-1 positive HSC/MFs (red fluorescence), of α-SMA (green fluorescence) plus DAPI nuclear counterstain (blue
fluorescence).
collagen Type I synthesis. 
On the other hand, a single study reported inhibition
of cell contraction during “in vitro” activation of rat
HSC/MFs by VEGF, an event that has been attributed to
a VEGF-dependent and Flt-1-mediated attenuation of α-
SMA expression (Mashiba et al., 1999). 
VEGF and Ang-1 as stimuli able to induce migration
of HSC/MFs
A final relevant finding that links hypoxia,
angiogenic cytokines and the profibrogenic role of these
cells is the observation that hypoxia-dependent up-
regulation and release of VEGF by human HSC/MFs can
stimulate, in a paracrine and/or autocrine manner, non-
oriented migration and chemotaxis of human HSC/MFs
(Novo et al., 2007), as shown by using the wound
healing assay or the modified Boyden’s chamber
technique. The effect of VEGF on migration and
chemotaxis was reported to be dose-dependent, with a
chemotactic action comparable to the one exerted by
PDGF-BB, used as positive control. Experimental
manipulations revealed that under hypoxic conditions
VEGF is progressively released by human HSC/MFs
and that the action of the cytokine mainly depends on its
interaction with VEGFR-2 or Flk-1 and on stimulation
of Ras/Erk signalling (Novo et al., 2007) as well as on
the activation of c-Jun N-terminal kinase isoforms
(JNKs) (Novo et al., 2008b, 2009, submitted). Moreover,
Ang-1, similarly to what was described for VEGF, was
found to stimulate non-oriented migration and
chemotaxis of human HSC/MFs (Novo et al., 2007).
These findings indicate that in a chronic inflammatory
and fibrotic environment, which is common to several
CLDs of different aetiology, VEGF and Ang-1, produced
and released by different cell populations in liver
parenchyma, including hepatocytes and endothelial cells
(VEGF) as well as pro-fibrogenic cells (VEGF, Ang-1),
may then contribute to recruit HSC/MFs. 
This finding is of general relevance if one considers
that migration of HSC/MFs, a distinctive feature of these
cells, can occur in response to a limited number of
chemoattractant polypeptides or reactive oxygen species
(ROS) which are generated during the development of
either acute or chronic liver injury (Pinzani and Marra,
2001; Friedman, 2003, 2008a,b; Novo et al., 2006;
Parola et al., 2008). However, the most relevant point is
that such a peculiar feature of HSC/MFs, pro-
inflammatory and pro-fibrogenic cells, which in turn are
able to both release angiogenic cytokines and migrate in
their presence, can offer an additional and significant
explanation of why these cells may align with
inflammatory and fibrotic septa (and neovessels) during
fibrosclerotic progression of CLDs, representing a
crucial cellular crossroad between the different
biological process. 
This interpretation is supported by recent “in vivo”
morphological data obtained in human and rat
fibrotic/cirrhotic livers, suggesting that α-SMA -
positive cells (i.e., myofibroblast-like phenotype) able to
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Fig. 6. Interface HSC/MFs (i.e.,
elements mainly found in HCV - related
fibrotic/cirrhotic livers) and, possibly,
other liver myofibroblasts of different
origin, may represent a cellular
phenotype potentially able to modulate
multiple and concomitant processes,
including not only fibrogenesis and
inflammation but also angiogenesis
and vascular/sinusoidal remodelling.
From one side, these cells seem to
represent a target for the multiple
action of VEGF and Ang-1, including
stimulation of collagen type I synthesis
and recruitment of HSC/MFs and MFs,
as well as, as already well established,
a target for the action of pro-
inflammatory mediators. At the same
time, these cells are also significant
sources of angiogenic cytokines,
particularly under hypoxic conditions
and acute and chronic liver injury,
possibly through the contribution of a
number of growth factors, pro-
inflammatory cytokines and conditions
of altered metabolic control, as recently
suggested by data indicating that leptin
is able to up-regulate VEGF. Morphological images. A. Indirect immunofluorescence of desmin positive rat HSCs on cryostat sections from normal liver
(green fluorescence) plus DAPI nuclear counterstain (blue fluorescence). B. Indirect immunofluorescence of α-SMA positive rat HSC/MFs on cryostat
sections from cirrhotic liver (red fluorescence) plus DAPI nuclear counterstain (blue fluorescence). 
express concomitantly VEGF, Ang-1 or the related
receptors Flk-1 and Tie-2, are found at the leading edge
of tiny and incomplete developing septa, but not in
larger bridging septa (Novo et al., 2007). This
distribution may indeed reflect two different phases of
the angiogenic process during chronic wound healing: an
early phase, occurring in developing septa, in which
fibrogenesis and angiogenesis may be driven/modulated
by HSC/MFs, and a later phase occurring in larger and
more mature fibrotic septa where the chronic wound
healing is less active and fibrogenic transformation more
established; in this latter setting pro-angiogenic factors
are expressed only by endothelial cells (see Figure 5), a
scenario that is likely to favour the stabilization of the
newly formed vessels. These findings may also suggest
that the efficacy of experimental anti-angiogenic therapy
(see section 5.3) in significantly preventing fibrosis
progression may also rely on the block of HSC/MFs
migration and chemotaxis. 
7. Concluding remarks
The literature data analysed in the present review
indicate that pathological angiogenesis can have a
significant role in CLDs characterized by chronic injury,
persisting inflammation and progressive fibrogenesis,
irrespective of aetiology, with an overall scenario in
which hypoxia and angiogenesis may emerge as
conditions able to favour fibrogenic progression of
CLDs also by sustaining the pro-fibrogenic behaviour of
liver MFs. The major takehome messages from this
review may be then summarized as follows:
1) Angiogenesis and fibrogenesis occur in parallel in
both clinical and experimental conditions of chronic
liver disease.
2) The literature data suggest that blocking
angiogenesis means also blocking fibrogenesis. 
3) Hypoxia should be considered as a major event in
eliciting angiogenesis, with hepatocytes and
profibrogenic cells being the most prominent sources of
VEGF; HSC/MFs also express Ang-1.
4) HSC/MFs and, probably, activated MF-like cells
of different origin, may represent (see Figure 6) a
cellular crossroad of more relevant processes in chronic
wound healing, both being able to release (autocrine and
paracrine way) angiogenic cytokines in response to
hypoxia, as well as responding to pro-fibrogenic action
of VEGF and Ang-1. 
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